Tranzyme Pharma Promotes David Moore to Chief Business Officer

Tranzyme Pharma Promotes David Moore to Chief Business Officer

RESEARCH TRIANGLE PARK, N.C., Jan. 15, 2013 (GLOBE NEWSWIRE) -- Tranzyme
Pharma (Nasdaq:TZYM) today announced that David S. Moore has been named as
Chief Business Officer.

"Dave has provided meaningful contributions and leadership since joining
Tranzyme said Vipin Garg, PhD, Tranzyme's President and Chief Executive
Officer. I look forward to working with him in his new role as we continue to
advance the Company."

Mr. Moore joined Tranzyme in August 2011 from Johnson & Johnson as Vice
President, Commercial Operations and his responsibilities were increased in
January 2012 to include the oversight of Business Development.

In his new role as Chief Business Officer, Mr. Moore will be responsible for
corporate development for the Company, including new discovery collaborations
and advancing new opportunities for clinical stage assets, in addition to an
increase in general management responsibilities.

About Tranzyme Pharma

Tranzyme Pharma is a biopharmaceutical company focused on discovering,
developing and commercializing novel, mechanism-based therapeutics for the
treatment of upper gastrointestinal (GI) motility disorders. While
approximately 40 percent of people in the U.S. are affected by these
persistent and recurring conditions which disrupt the normal movement of food
throughout the GI tract, there are a limited number of safe and effective
treatment options. By leveraging its proprietary drug discovery technology,
MATCH™, Tranzyme is committed to pursuing first-in-class medicines to address
areas of significant unmet medical needs.

Further information about Tranzyme Pharma can be found on the Company's
website at www.tranzyme.com.

Forward-Looking Statements

Statements in this press release may include statements which are not
historical facts and are considered forward-looking within the meaning of
Section 27A of the Securities Act and Section 21E of the Securities Exchange
Act, which are usually identified by the use of words such as "anticipates,"
"believes," "estimates," "expects," "intends," "may," "plans," "projects,"
"seeks," "should," "will," and variations of such words or similar
expressions. We intend these forward-looking statements to be covered by the
safe harbor provisions for forward-looking statements contained in Section 27A
of the Securities Act and Section 21E of the Securities Exchange Act and are
making this statement for purposes of complying with those safe harbor
provisions. These forward-looking statements reflect our current views about
our plans, intentions, expectations, strategies and prospects, including new
collaborations and opportunities, which are based on the information currently
available to us and on assumptions we have made. Although we believe that our
plans, intentions, expectations, strategies and prospects as reflected in or
suggested by those forward-looking statements are reasonable, we can give no
assurance that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be affected by a
variety of risks and factors that are beyond our control including, without
limitation, risks related to enrollment and successful completion of our
trials, risk of unforeseen side effects, risks related to our collaborations
and risks related to regulatory approval of new drug candidates. Further
information on these and other factors that could affect the company's
financial results is contained in our public filings with the Securities and
Exchange Commission (SEC) from time to time, including our Form 10-Q for the
quarter ended September 30, 2012 which was filed with the SEC on November 9,
2012, and subsequent filings with the SEC. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. We assume no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com
        
         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
         dcarey@lazarpartners.com
 
Press spacebar to pause and continue. Press esc to stop.